TrialThe Journal of thoracic and cardiovascular surgery2023

Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancer.

Valerie W Rusch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.